Dyne Therapeutics(DYN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early January 2025 - - Enrolling Registrational Cohort of DYNE-251 DELIVER Trial in DMD - WALTHAM, Mass., November 12, 2024 – Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ...